Amendment: SEC Form SC 13G/A filed by BioXcel Therapeutics Inc.

9/10/24 10:47:52 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $BTAI alert in real time by email

SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.9 BIOXCEL THERAPEUTICS INC COMMON STOCK Cusip #09075P105 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #09075P105 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 1,075,324 Item 6: 0 Item 7: 1,075,324 Item 8: 0 Item 9: 1,075,324 Item 11: 2.639% Item 12: HC Cusip #09075P105 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 1,075,324 Item 8: 0 Item 9: 1,075,324 Item 11: 2.639% Item 12: IN Item 1(a). Name of Issuer: BIOXCEL THERAPEUTICS INC Item 1(b). Address of Issuer's Principal Executive Offices: 555 LONG WHARF DRIVE NEW HAVEN, CT 06511 USA Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 09075P105 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 1,075,324 (b) Percent of Class: 2.639% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 1,075,324 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof, the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following (X). Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of BIOXCEL THERAPEUTICS INC. No one other person's interest in the COMMON STOCK of BIOXCEL THERAPEUTICS INC is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. September 9, 2024 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification Fidelity Management & Research Company LLC IA Fidelity Management Trust Company BK Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on September 9, 2024, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of BIOXCEL THERAPEUTICS INC at August 30, 2024. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.

Get the next $BTAI alert in real time by email

Date	Price Target	Rating	Analyst
2/21/2024	$9.00 → $4.00	Buy → Neutral	UBS
8/15/2023	$40.00 → $4.00	Buy → Neutral	Mizuho
7/17/2023		Buy → Neutral	Guggenheim
3/10/2023	$20.00 → $22.00	Buy → Hold	Jefferies
12/1/2022	$16.00	Sell → Neutral	Goldman
7/7/2022	$19.00	Buy	Mizuho
4/6/2022	$80.00	Buy	BofA Securities
2/16/2022	$88.00 → $25.00	Buy	UBS

Amendment: SEC Form SC 13G/A filed by BioXcel Therapeutics Inc.

Chat with this insight

Recent Analyst Ratings for
$BTAI

$BTAI
FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

FDA Approval for IGALMI issued to BIOXCEL THERAPEUTICS, INC.

$BTAI
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Mack David J. converted options into 1,693 shares, increasing direct ownership by 33% to 6,772 units (SEC Form 4)

Director Mack David J. converted options into 27,089 shares, increasing direct ownership by 50% to 81,267 units (SEC Form 4)

SEC Form 4 filed by Director Patni Rajiv

$BTAI
Financials

Live finance-specific insights

$BTAI
SEC Filings

$BTAI
Press Releases

Fastest customizable press release news feed in the world

$BTAI
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

$BTAI
Large Ownership Changes

This live feed shows all institutional transactions in real time.

BioXcel Therapeutics Reports Third Quarter 2024 Financial Results

BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024

BioXcel Therapeutics Reports Second Quarter 2024 Financial Results

BioXcel Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

SEC Form 424B5 filed by BioXcel Therapeutics Inc.

BioXcel Therapeutics Inc. filed SEC Form 8-K: Other Events

BioXcel Therapeutics Strengthens Cash Position to Advance SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

BioXcel Therapeutics Announces 33% Enrollment in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

BioXcel Therapeutics Announces Closing of $14 Million Registered Direct Offering

BioXcel Therapeutics downgraded by UBS with a new price target

BioXcel Therapeutics downgraded by Mizuho with a new price target

BioXcel Therapeutics downgraded by Guggenheim